Health ❯ Pharmaceuticals

Generic Drugs

Atorvastatin FDA Regulations Semaglutide Market Dynamics Regulatory Issues Efficacy Concerns Biosimilars Cardiovascular Medications Weight Loss Medications Market Availability Supply Chain Drug Pricing US Market Impact Access to Medicines Safety Reviews Market Access Drug Manufacturing Cancer Treatment Weight Loss Cost Plus Drugs Global Production Market Impact Multiple Sclerosis Treatments US Government Programs

FDA Class II Recall Issued for 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

Regulators urge patients to consult a clinician before making any medication changes.

FDA Class II Recall Targets 142,000 Bottles of Ascend’s Atorvastatin

FDA Confirms Safety Review of Mifepristone With No Regulatory Changes Yet

Chinese Weight-Loss Drug Suppliers Pivot to Generics as U.S. Crackdown Ends Copycat Boom